Teva Pharmaceuticals said Friday a US federal appeals court had barred the company from selling its generic version of Pravachol, until the court has considered the outstanding dispute, which centers on rival generic drug maker Apotex's contention that exclusivity to manufacture the cholesterol drug should be granted to the Canadian firm, rather than to Teva.
Separately, Teva said it received tentative FDA approval for its generic version of Wyeth's Protonix tablets. Marketed under the name Pantoprazole, Teva's version of Protonix will be used to treat erosive esophagitis and hypersecretory conditions. US brand sales of the drug were about $2.4 billion in 2005.
Teva is currently in patent litigation on Pantoprazole. Final approval was expected by August 2007.